Till-Karsten Hauser

Nov 26, 2024 | mdpi.com | Patrick Tyler Haas |Till-Karsten Hauser |Lucas Moritz Wiggenhauser |Leonie Zerweck

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 10, 2024 | nature.com | Pauline Latzer |Florian Battke |Till-Karsten Hauser |Christian la Fougère |Uwe M. Martens |Deborah Blumenthal | +8 more

AbstractCurrent treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt.